Addressing the Measles-Mumps-Rubella Revaccination Guidelines for Allogenic Bone Marrow Transplant Patients: A Response to the American Society for Transplantation and Cellular Therapy 2019 Position Statement
The American Society for Transplantation and Cellular Therapy position statement on measles-mumps-rubella (MMR) prevention in immunocompromised cancer and hematopoietic cell transplant patients by Pergam et al. [1] addresses many concerns both providers and patients have about measles prevention post-transplant. However, we are skeptical about the data regarding the safety of the MMR vaccination guidelines for patients after allogenic bone marrow transplant as stated in this article.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Kevin Perez, Vivek V. Shah, Gary J. Schiller Source Type: research
More News: Biology | Bone Marrow Transplant | Cancer | Cancer & Oncology | Cancer Vaccines | Hematology | Measles | Measles Vaccine | Mumps | Mumps Vaccine | Rubella | Rubella Vaccine | Transplants | Vaccines